PL EN


Preferences help
enabled [disable] Abstract
Number of results
2011 | 58 | 1 | 59-65
Article title

Advanced oxidation protein products and inflammatory markers in liver cirrhosis: a comparison between alcohol-related and HCV-related cirrhosis

Content
Title variants
Languages of publication
EN
Abstracts
EN
Advanced oxidation protein products (AOPPs) are protein markers of oxidative stress with pro-inflammatory properties that accumulated in liver cirrhosis. In the present study, we investigated the association between chronic inflammatory response triggered by AOPPs and the severity of liver disease as assessed by the Child-Pugh score. Plasma concentrations of AOPPs and inflammatory markers such as C-reactive protein, tumor necrosis factor-α, and interleukin-6 were measured in 41 patients with HCV-related cirrhosis, 43 patients with alcohol-related liver cirrhosis (ALC), and in 30 age and sex matched controls. In comparison with controls, AOPPs were increased in HCV-related compensated (Child-Pugh A) and decompensated (Child-Pugh B-C) cirrhosis and in alcohol-related compensated cirrhosis. AOPPs level positively correlated with Child-Pugh score in alcohol-related cirrhosis but not in HCV-related cirrhosis and the correlation with the indices of chronic inflammation was stronger in ALC. In turn, AOPPs in HCV-related cirrhosis was related to inflammation to a lesser extent, but a significant correlation with antioxidant defense could be noted. In summary, liver cirrhosis was associated with increased formation of AOPPs, which differed between alcohol-related and HCV-related cirrhosis with respect to the relationship between AOPPs and antioxidant defense, stage of liver cirrhosis, and inflammatory response. The significant correlation between AOPPs accumulation and indices of chronic inflammation, more specifically TNF-α, suggests that oxidative stress may be a mediator of chronic inflammatory state in the early stage of alcohol-related cirrhosis.
Publisher

Year
Volume
58
Issue
1
Pages
59-65
Physical description
Dates
published
2011
received
2010-08-02
revised
2010-11-23
accepted
2011-03-09
(unknown)
2011-03-14
Contributors
  • Department of Pharmaceutical Biochemistry, Liver Diseases and Acquired Immune Deficiency, Wrocław Medical University, Wrocław, Poland
  • Clinic of Infectious Diseases, Liver Diseases and Acquired Immune Deficiency, Wrocław Medical University, Wrocław, Poland
  • Clinic of Infectious Diseases, Liver Diseases and Acquired Immune Deficiency, Wrocław Medical University, Wrocław, Poland
author
  • Department of Pharmaceutical Biochemistry, Liver Diseases and Acquired Immune Deficiency, Wrocław Medical University, Wrocław, Poland
References
  • Alderman ChJ, Shah S, Foreman JC, Katz DR (2002) The role of advanced oxidation protein products in regulation of dendritic cell function. Free Radic Biol Med 32: 377-385.
  • Ballou SP, Lozanski G (1992) Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 4: 361-368.
  • Baskol G, Demir H, Baskol M, Kilic E, Ates F, Karakukcu C, Ustdal M (2006) Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid artritis. Cell Biochem Funct 24: 307-311.
  • Bierhaus A, Stern DM, Nawroth PP (2006) RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 7: 985-991.
  • Black S, Kushneri I, Samols D (2004) C-reactive protein. J Biol Chem 279: 48487-49490.
  • Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M (1989) Prolonged activation of jun and collagenase genes by tumour necrosis factor alpha. Nature 337: 661-663.
  • Caregaro L, Alberino F, Amodio P, Merkel C, Bolognesi M, Angeli P, Gatta A (1996) Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr 63: 602-609.
  • Czeczot H, Scibior D, Skrzycki M, Podsiad M (2006) Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma. Acta Biochim Pol 53: 237-242.
  • De Maria N, Colantoni A, Fagiuoli S, Liu GJ, Rogers BK, Farinati F, Van Thiel DH, Floyd RA (1996) Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med 21: 291-295.
  • Ekong U, Zeng S, Dun H, Feirt N, Guo J, Ippagunta N, Guarrera JV, Lu Y, Weinberg A, Qu W, Ramasamy R, Schmidt AM, Emond JC (2006) Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice. J Gastroenterol Hepatol 21: 682-688.
  • Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R (1995) Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 22: 449-456.
  • Fialova L, Malbohan I, Kalousova M, Soukupova J, Krofta L, Stipek S, Zima T (2006) Oxidative stress and inflammation in pregnancy. Scand J Clin Lab Invest 66: 121-127.
  • Girón-González JA, Martínez-Sierra C, Rodriguez-Ramos C, Macías MA, Rendón P, Díaz F, Fernández-Gutiérrez C, Martín-Herrera L (2004) Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver Int 24: 437-445.
  • Górka J, Zuwała-Jagiełło J, Pazgan-Simon M, Simon K, Warwas M (2008) Fluorescence of age in serum in detecting liver cirrhosis and hepatocellular carcinoma among patients with anti-HCV antibodies. Przegl Epidemiol 62: 393-400.
  • Guo ZJ, Niu HX, Hou FF, Zhang L, Fu N, Nagai R, Lu X, Chen BH, Shan YX, Tian JW, Nagaraj RH, Xie D, Zhang X (2008) Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 10: 1699-1712.
  • Hanck C, Glatzel M, Singer MV, Rossol S (2000) Gene expression of TNF-receptors in peripheral blood mononuclear cells of patients with alcoholic cirrhosis. J Hepatol 32: 51-57.
  • Hyogo H, Yamagishi S (2008) Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 14: 969-972.
  • Jain SK, Pemberton PW, Smith A, McMahon RF, Burrows PC, Aboutwerat A, Warnes TW (2002) Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol 36: 805-811.
  • Kalousova M, Skrha J, Zima T (2002) Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51: 597- 604.
  • Kalousová M, Zima T, Tesar V, Dusilová-Sulková S, Skrha J (2005) Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res 579: 37-46.
  • Kirkham P (2007) Oxidative stress and macrophage function: a failure to resolve the inflammatory response. Biochem Soc Trans 35: 284-287.
  • Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, Weinman SA (2005) Hepatitis c virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ros) production. J Biol Chem 280: 37481-3788.
  • Li JT, Hou FF, Guo ZJ, Shan YX, Zhang X, Liu ZQ (2007) Advanced glycation end products upregulate C-reactive protein synthesis by human hepatocytes through stimulation of monocyte IL-6 and IL-1 beta production. Scand J Immunol 66: 555-562.
  • Marsche G, Frank S, Hrzenjak A, Holzer M, Dirnberger S, Wadsack C, Scharnagl H, Stojakovic T, Heinemann A, Oettl K (2009) Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res 104: 750-757.
  • Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C (2003) Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 34: 1563-1574.
  • Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM (2001) Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 47: 426-430.
  • Miyata TR, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda K, Seo H (1994) Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin-1. J Clin Invest 93: 521-528.
  • Murakami T, Kim T, Nakamura H (1998) Hepatitis, cirrhosis, and hepatoma. J Magn Reson Imaging 8: 346-358.
  • Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA (2002) Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122: 366-375.
  • Paradis V, Kollinger M, Fabre M, Holstege A, Poynard T, Bedossa P (1997) In situ detection of lipid peroxidation by products in chronic liver diseases. Hepatology 26: 135-142.
  • Pepys MB, Berger A (2001) The renaissance of C reactive protein (Editorials). BMJ 322: 4-5.
  • Plauth M, Schutz ET (2002) Cachexia in liver cirrhosis. Int J Cardiol 85: 83-87.
  • Romiti A, Merli M, Martorano M, Parrilli G, Martino F, Riggio O, Truscelli A, Capocaccia L, Budillon G (1990) Malabsorption and nutritional abnormalities in patients with liver cirrhosis. Ital J Gastroenterol 22: 118-123.
  • Saito H, Ishii H (2004) Recent understanding of immunological aspects in alcoholic hepatitis. Hepatol Res 30: 193-198.
  • Saitoh O, Sugi K, Lojima K, Matsumoto H, Nakagawa K, Kayazawa M, Tanaka S,Teranishi T, Hirata I, Katsu Ki K (1999) Increased prevalence of intestinal inflammation in patients with liver cirrhosis. World J Gastroenterol 5: 391-396.
  • Schwedler S, Schinzel R, Vaith P, Wanner C (2001) Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int Suppl 78: S32-36.
  • Sebekova KV, Kupcova R, Schinzel A, Heidland J (2002) Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. J Hepatol 36: 66-71.
  • Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT (2009) RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 7: 17-38.
  • Strassmann G, Fong M, Kenney JS, Jacob CO (1992) Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89: 1681-1684.
  • Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier G, Huber C (1992) Serum levels of cytokines in chronic liver diseases. Gastroenterology 103: 264-274.
  • Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84.
  • Videla LA (2009) Oxidative stress signaling underlying liver disease and hepatoprotective mechanisms World J Hepatol 1: 72-78.
  • Vlassara H, Moldawer L, Chan B (1989) Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor. J Clin Invest 84: 1813-1820.
  • Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S (2003) C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107: 1783-1790.
  • Witko-Sarsat V, Friedlander M, Capelliere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-1313.
  • Witko-Sarsat V, Friedlander M, Khoa TN, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer J-M, Jungers P, Drueke T, Descamps-Latscha B (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161: 2524-2532.
  • Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drüeke T, Santangelo F, Descamps-Latscha B (2003) AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylc-cysteine treatment in dialysis patients. Kidney Int 64: 82-91.
  • Woods AA, Davies MJ (2003) Fragmentation of extracellular matrix by hypochlorous acid. Biochem J 376: 219-227.
  • Yagmur E, Tacke F, Weiss C, Lahme B, Manns MP, Kiefer P, Trautwein C, Gressner AM (2006) Elevation of Nε-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. Clin Biochem 39: 39-45.
  • Yazici C, Köse K, Calis M, Kuzugüden S, Kirnap M (2004) Protein oxidation status in patients with ankylosing spondylitis. Rheumatology 43: 1235-1239.
  • Zuwała-Jagiełło J, Simon K, Pazgan-Simon M, Kość-Czarny A, Warwas M (2006) Advanced glycation end products in serum of patients with chronic hepatitis and liver cirrhosis. Adv Clin Exp Med 2: 259-264.
  • Zuwała-Jagiełło J, Pazgan-Simon M, Simon K, Warwas M (2009) Elevated advanced oxidation protein products levels in patients with liver cirrhosis. Acta Biochim Pol 56: 679-685.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv58i1p59kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.